New York-based Intercept Pharmaceuticals, Inc . ICPT focused on bringing novel therapeutics to treat chronic liver diseases to market.
Intercept received a major boost with the FDA approval (in May 2016) of its lead drug, Ocaliva, in combination with ursodeoxycholic (UDCA), for the treatment of primary biliary cholangitis (PBC) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
The FDA approved Ocaliva under its accelerated approval program based on a reduction in alkaline phosphatase (ALP), since an improvement in survival or disease-related symptoms has not been established yet. Continued approval in this indication may be contingent upon the verification and description of clinical benefit in confirmatory studies. In Dec 2016, the European Commission granted conditional approval to Ocaliva for the same indication. Meanwhile, Ocaliva is being evaluated for other indications including non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
Intercept's track record has been decent so far, with the company surpassing expectations in three of the last four quarters. The company has posted an average positive surprise of 1.12% over this period.
Intercept Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Currently, Intercept Pharma has a Zacks Rank #2 (Buy), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : Our consensus called for a loss of $2.83, while the company reported a loss of $2.58.
Revenue : Intercept Pharma posted revenues of $43.6 million which also beat our consensus estimate of $39.9 million.
Key Stats : Ocaliva sales came in at $43.2 million, up from $30.4 million in the year-ago quarter. The company reiterated its previously announced 2018 sales guidance range of between $170 million and $185 million for Ocaliva.
Check back later for our full write up on this ICPT earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.